A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)

Antzeko izenburuak

• A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)
  nork: C. Robert, et al.
  Argitaratua: (2026-01-01)
• Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
  nork: Zhikun Guo, et al.
  Argitaratua: (2024-03-01)
• Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade
  nork: Paul Bergeron, et al.
  Argitaratua: (2024-10-01)
• Gene Signatures as Predictive Biomarkers for PD-1 Blockade in Cutaneous Squamous Cell Carcinoma
  nork: K. Schaper-Gerhardt, et al.
  Argitaratua: (2026-01-01)
• A Rare Case of Acquired Reactive Perforating Collagenosis in a Child With Type 1 Diabetes
  nork: R.P. Román Cheuque, et al.
  Argitaratua: (2026-03-01)